
Insulet Corporation PODD
$ 221.0
-2.0%
Quarterly report 2025-Q3
added 03-14-2026
Insulet Corporation Accounts Payables 2011-2026 | PODD
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75 M | 19.8 M | 19.2 M | 30.8 M | 37.7 M | 54.1 M | 54.5 M | 25.5 M | 24.4 M | 13.2 M | 15.2 M | 14.7 M | 19.4 M | 9.36 M | 11.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 75 M | 9.36 M | 28.3 M |
Quarterly Accounts Payables Insulet Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.2 M | 96.1 M | 57.6 M | 19.8 M | 40.3 M | 76.8 M | 75.9 M | 19.2 M | 77.8 M | 108 M | 85.9 M | 30.8 M | 62.1 M | 57.2 M | 52.2 M | 37.7 M | 58 M | 49.3 M | 59.1 M | 54.1 M | 57 M | 35.6 M | 36.4 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 25.5 M | 25.5 M | 25.5 M | 25.5 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 12.6 M | 14.7 M | 14.7 M | 14.7 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 9.36 M | 9.36 M | 9.36 M | 9.36 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 108 M | 9.36 M | 34.6 M |
Accounts Payables of other stocks in the Medical devices industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Orthofix Medical
OFIX
|
58.4 M | $ 11.78 | 0.51 % | $ 467 M | ||
|
Axonics Modulation Technologies
AXNX
|
9.07 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
4.79 M | - | 1.37 % | $ 20.5 M | ||
|
Delcath Systems
DCTH
|
2.66 M | $ 9.35 | 4.12 % | $ 335 M | ||
|
Acutus Medical
AFIB
|
2.76 M | - | -26.83 % | $ 2.62 M | ||
|
Penumbra
PEN
|
34.7 M | $ 335.59 | 0.4 % | $ 13.1 B | ||
|
Allied Healthcare Products
AHPI
|
1.21 M | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
817 K | - | -0.97 % | $ 54.4 M | ||
|
Conformis
CFMS
|
4.16 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
14.4 M | - | 0.15 % | $ 844 M | ||
|
Apollo Endosurgery
APEN
|
7.42 M | - | - | $ 475 M | ||
|
IRadimed Corporation
IRMD
|
1.82 M | $ 101.26 | 0.29 % | $ 1.29 B | ||
|
Avinger
AVGR
|
777 K | - | -20.74 % | $ 369 K | ||
|
CONMED Corporation
CNMD
|
93.6 M | $ 36.45 | -0.37 % | $ 1.13 B | ||
|
Sintx Technologies
SINT
|
382 K | $ 2.6 | 1.17 % | $ 7.21 M | ||
|
NanoVibronix
NAOV
|
47 K | - | - | $ 1.08 M | ||
|
Electromed
ELMD
|
2.67 M | $ 24.7 | - | $ 209 M | ||
|
MiMedx Group
MDXG
|
14.5 M | $ 4.11 | -0.61 % | $ 607 M | ||
|
Sensus Healthcare
SRTS
|
1.2 M | $ 4.18 | 5.43 % | $ 68.2 M | ||
|
Cytosorbents Corporation
CTSO
|
3.34 M | $ 0.67 | -3.71 % | $ 36.5 M | ||
|
Aethlon Medical
AEMD
|
535 K | $ 2.31 | 6.94 % | $ 3.61 M | ||
|
BIOLASE
BIOL
|
6.06 M | - | -13.19 % | $ 166 K | ||
|
Stryker Corporation
SYK
|
1.8 B | $ 325.47 | -0.95 % | $ 124 B | ||
|
Tactile Systems Technology
TCMD
|
4.97 M | $ 27.52 | 2.46 % | $ 629 M | ||
|
InspireMD
NSPR
|
1.26 M | $ 1.79 | - | $ 115 M | ||
|
AdaptHealth Corp.
AHCO
|
352 M | $ 11.4 | -0.7 % | $ 1.54 B | ||
|
Myomo
MYO
|
1.51 M | $ 0.7 | 0.47 % | $ 29.3 M | ||
|
Tandem Diabetes Care
TNDM
|
47.1 M | $ 24.0 | -2.08 % | $ 1.63 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
2.21 M | $ 2.34 | -2.71 % | $ 137 M | ||
|
Invacare Corporation
IVC
|
105 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
5.71 M | $ 3.7 | -5.37 % | $ 138 M | ||
|
Quanterix Corporation
QTRX
|
13.6 M | $ 3.94 | 3.14 % | $ 168 M | ||
|
OrthoPediatrics Corp.
KIDS
|
18.8 M | $ 16.16 | 1.57 % | $ 379 M | ||
|
Outset Medical
OM
|
554 K | $ 3.48 | -1.42 % | $ 52.9 K |